In HCC chemotherapy, a well-tolerated combination of sorafenib and valproic acid was found to synergistically inhibit tumor growth by downregulating Notch3 and p-Akt (Zhu et al., 2017). This evidence concerns the gene NOTCH3 and neoplasm.